AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
AstraZeneca plc (NYSE: AZN) is in advanced discussions with U.S. rival Bristol-Myers Squibb (BMS, NYSE:...
Roche’s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China’s National Medical Products Administration (NMPA)...
Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its development partner Caldera Therapeutics has entered...
Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration...
Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application...
Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034...
CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate...
MicroPort NeuroScientific’s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China’s First Targeted-Release Self-Expanding System
MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting...
China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector
China Resources Pharmaceutical Group Limited (HKG: 3320) announced a definitive agreement to acquire 188,102,749 shares...
Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1...
Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US
Xgene Pharmaceutical Inc. announced the successful completion of a RMB 250 million ($35 million) Series...
Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval
Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to...
Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes
Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) announced plans to initiate a Phase Ib...
GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced plans to establish a major new global R&D center...
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)...
Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership
Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...
Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial
Shionogi & Co., Ltd. (TYO: 4507) announced the U.S. commercial availability of XOCOVA (ensitrelvir), an...
Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma
Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...
Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials
Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial...
TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform
TPMeds announced the successful completion of an Angel financing round amounting to tens of millions...